Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

11.12 -0.04 (-0.40%)

Delayed Quote Updated: 11:44 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗

February 21, 2023

Via Benzinga

DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

February 21, 2023

Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 21, 2023

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

February 20, 2023

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

January 30, 2023

Via Benzinga

Analyst Expectations for Vir Biotechnology's Future ↗

January 27, 2023

Via Benzinga

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

February 16, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology Appoints Sung Lee as Chief Financial Officer

February 16, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out ↗

February 14, 2023

Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.

Via Benzinga

Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

February 14, 2023

Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,...

Via Benzinga

2 Fast-Growing Healthcare Stocks to Buy and Hold ↗

December 02, 2022

The innovative companies have made great gains in a short period of time.

Via The Motley Fool

Data From Multiple Ongoing Trials Of Vir Biotech's HBV Therapies Show Promising Action ↗

November 07, 2022

Via Benzinga

Why Vir Biotechnology Jumped Nearly 19% Today ↗

November 04, 2022

A COVID-19 partnership with a major drugmaker is producing more fruit than expected.

Via The Motley Fool

Vir Biotechnology Announces Amended Collaboration Agreement with GSK

February 13, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Insiders Selling Meta Platforms And 3 Other Stocks ↗

February 10, 2023

The Nasdaq dropped by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

The 7 Most Undervalued Biotech Stocks to Buy in February 2023 ↗

February 02, 2023

Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.

Via InvestorPlace

7 Healthcare Stocks That Will Be Big Winners in 2023 ↗

January 31, 2023

Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗

January 27, 2023

Via Benzinga

Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor

January 25, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

2 Stocks That Could Turn $100 Into $1,000 by 2028 ↗

January 22, 2023

These growth stocks have substantial tailwinds.

Via The Motley Fool

Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A

December 21, 2022

– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 –

From Vir Biotechnology, Inc.

Via GlobeNewswire

BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts ↗

December 02, 2022

Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...

Via Benzinga

European Official Says COVID-19 Booster Uptake Disappointing In The Region ↗

November 25, 2022

Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...

Via Benzinga

After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade ↗

November 18, 2022

Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.

Via Benzinga

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™

November 16, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗

November 16, 2022

Via Benzinga

FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting ↗

November 15, 2022

Via Benzinga

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection

November 06, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday ↗

November 07, 2022

Gainers

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.